AKT1 and endometriosis: Despite the growing interest in the PI3K/Akt/mTOR signalling pathway in endometriosis, there is still a significant gap in understanding the role and toxicity management of mTOR inhibitors, the only class of PI3K/Akt/mTOR pathway inhibitors with a long history of clinical use.